Vice President, US Regulatory Affairs
Hikma Pharmaceuticals USA Inc.
Dawn Culp currently serves as VP, US Regulatory Affairs at Hikma Pharmaceuticals USA Inc. based in Berkeley Heights, NJ, USA. She is a 34-year generic industry veteran, having spent 29 years at the management level at Novopharm (now Teva), Apotex, Mylan (now Viatris) and now Hikma. Over the years, she has had regulatory responsibility for Canada, United States and South America, working closely on matters with Health Canada and the US FDA while leading teams in Development RA, Post-Approval RA, RA Policy, RA Support, Pharmacovigilance and Biopharmaceutics.
Dawn has an Honors Bachelor of Science in Pharmacology from the University of Toronto and has participated in various senior leadership development programs.
She has had extensive experience as a representative on many industry and professional association committees within the CGPA, AAM, Medicines for Europe and IGBA, including Past Chairman of the Scientific Affairs Committee at the CGPA. In these positions, Dawn has represented the industry at many government meetings and with many levels of government.